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Introduction
Lysosomal storage diseases (LSDs) comprise more than 50 disorders caused by inborn errors of metabolism, which involve the impaired function of endosome-lysosome proteins. 1 In LSDs, defects in genes encoding lysosomal hydrolases, transporters, or enzymatic activators result in macromolecule accumulation in the late endocytic system. 2 The disruption of lysosomal homeostasis is linked to increased endoplasmic reticulum and oxidative stress, which not only is a common mediator of apoptosis in LSDs but also can induce oncogenic cellular phenotype and promote development of malignancy. 3, 4 Typical LSD patients have severely impaired organ functions and short life expectancy.
However, a considerable number of undiagnosed LSD patients have mildly impaired lysosomal function and survive into adulthood. 1 These patients are often diagnosed after they develop secondary diseases such as Parkinsonism that is attributable to insidious LSDs. 5 Clinical observations have also shown that the patients with Gaucher disease or Fabry disease are at increased risk of cancer, indicating the link between dysregulated lysosomal metabolism and carcinogenesis. 6, 7 However, the precise relationship between the lysosomal dysfunction and cancer remains unclear; this uncertainty can be attributed in part to the diverse and nonspecific phenotypes of LSDs and the resulting difficulty in recognizing patients with mild symptoms. The extensive allelic heterogeneity and the complex genotype-phenotype relationships make the diagnosis more challenging. 8 Furthermore, growing evidence suggests that the single allelic loss is also functionally significant, even though the impact may not be sufficient to develop overt disease. 9 Considering the above along with the recessive inheritance nature of most LSDs, we hypothesized that there would be a large number of undetected carriers of LSD-causing mutations with mild functional impairment, and these carriers would be at increased risk of cancer.
Here we report the results of a comprehensive association analysis between potentially pathogenic germline mutations in LSD-related genes and cancer using data from global sequencing projects. We aimed to elucidate the oncogenic potential of these mutations in a histology-specific manner. Potential carcinogenic mechanisms were also investigated using tumor genomic and transcriptomic data with a focus on the pancreatic adenocarcinoma.
Methods

Study populations
We used matched tumor-normal pair whole genome and tumor whole transcriptome sequences and the clinical data of 2567 cancer patients (Pan-Cancer cohort) from the International Cancer Genome Consortium (ICGC)/The Cancer Genome Atlas (TCGA) Pan-Cancer Analysis of Whole Genomes (PCAWG) project. 10 As controls, we used publicly available variant call sets from two global sequencing projects of individuals without known cancer histories. The first control data set comprised 2504 genomes from the 1000 Genomes project (1000 Genomes cohort). 11 The second data set contained exomes of 53105 unrelated individuals from a subset of the Exome Aggregation Consortium release 1.0 that did not include TCGA subset (ExAC cohort).
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Potentially pathogenic variant selection
Through an extensive literature review, we identified 42 LSD genes (Table 1) . 1, 8, [13] [14] [15] The potentially pathogenic variants (PPVs) that showed strong evidence of disease causation or functional defect were selected based on their consequence on transcripts or proteins, clinical and experimental evidence obtained from curated databases and medical literature, and in silico prediction of mutational effects on protein function. PPV selection was carried out using these three positive selection criteria and an automated algorithm-based approach. The PPVs were grouped into three tiers with partial overlaps, each tier corresponding to one of the selection criteria ( Figure S1 in the Supplementary Appendix).
Statistical analysis
A two-step approach was used to examine the association between PPVs and cancer. In the first step, the Pan-Cancer and 1000 Genomes cohorts were analyzed with the optimal sequence kernel association test (SKAT-O) for rare variant association and Fisher's exact test and logistic regression for direct comparison of mutation prevalence. 16 We adjusted for population structure using principal component analysis on 10494 tag single nucleotide polymorphisms ( Figure S2 and S3 in the Supplementary Appendix). The second step used the ExAC cohort as a control population, confined the analysis to protein-coding regions covered by more than half of the ExAC exomes, and used Fisher's exact tests to validate the preceding results. Age at diagnosis of cancer was compared using Wilcoxon rank sum tests and linear regression. Differentially expressed gene (DEG) and gene set analyses were performed using the DESeq2 Bioconductor package and generally applicable gene set enrichment (GAGE) method based on the framework of the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, respectively. [17] [18] [19] Correction for multiple testing was conducted using the false discovery rate (FDR) estimation procedure, and the tail area-based FDR (also referred to as q-value) was reported. 20 All tests were two-tailed unless otherwise specified. We considered FDR<0.1 or P<0.05 (when not adjusted for multiple testing) significant. Statistical analysis was performed using R version 3. 
Results
Characteristics of study cohorts
The Pan-Cancer cohort consisted of four populations and 38 histological subtypes of pediatric or adult cancer ( Figure 1 and Table S1 in the Supplementary Appendix). The median age at diagnosis of cancer was 60 years (range, 1 to 90). The most common populations were European and American in most cancer types. The 1000 Genomes cohort comprised five populations; we combined the European and American populations for comparison with the Pan-Cancer cohort.
11
Seven populations were represented in the ExAC cohort, among which the American and NonFinnish European accounted for more than 60% collectively.
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PPV prevalence in the Pan-Cancer and 1000 Genomes cohorts
In the 42 LSD genes, 7187 germline single nucleotide variants and small insertions and deletions in protein-coding regions, essential splice junctions, and 5' and 3' untranslated regions were identified in the aggregate variant call set of the Pan-Cancer and 1000 Genomes cohorts ( Figure S4 in the Supplementary Appendix). Of those, 4019 (55.9%) were singletons (variants found in only one individual), and 3′ untranslated region variants accounted for the largest proportion (37.7%).
Using a predefined algorithm, a total of 432 PPVs were selected within 41 genes; LAMP2 contained no PPVs ( Figure S5A and ; Figure 2A ). This association remained significant after adjustment for population structure (OR, 1.44; 95% CI, 1.22-1.71; P=2.4×10 -5 ). The ORs for cancer risk were higher in individuals with a greater number of PPVs. This tendency was broadly consistent across individual tiers, although some differences were not significant for each tier.
For comparison, we also examined the prevalence of rare synonymous variants (RSVs) with mean allele frequency <0.5% and found that it did not differ between the Pan-Cancer and 1000
Genomes cohort after adjustment for population structure, indicating that the enrichment of the Pan-Cancer cohort for PPVs was not likely due to batch effects ( Figure 2B ). The gene-specific prevalence of PPVs and RSVs in each cohort is shown in Figure S5B and S5C in the Supplementary Appendix, respectively. The results show that PPVs were relatively more abundant in the Pan-Cancer cohort versus the 1000 Genomes cohort with respect to the abundance of RSVs, for 33 of the 42 genes (78.6%; exact binomial test P<0.001).
Association of PPVs with histological subtypes of cancer
Among the 30 major histological subtypes of cancer (>15 individuals per subtype), the PPV prevalence ranged from 8.8% to 48.6%, and it was significantly higher in seven subtypes of cancer than in the 1000 Genomes cohort ( Figure Figure 2C ).
PPV prevalence in the Pan-Cancer and ExAC cohorts
Validation was conducted for (1) the eight cancer cohorts with significantly higher PPV prevalence than that of the 1000 Genomes cohort and (2) 10 PPV sets significantly associated with the Pan-Cancer cohort or three or more histological subtypes of cancer identified in the preceding SKAT-O analysis. As shown in Figure S7A , PPV prevalence was higher in all eight cancer cohorts than in the ExAC cohort, and this difference was significant for the Pan-Cancer, pancreatic adenocarcinoma, medulloblastoma, pancreatic neuroendocrine carcinoma, and osteosarcoma cohorts. In addition, all tested PPV sets except GBA were more prevalent in the Pan-Cancer cohort than in the ExAC cohort, and six were significantly different ( Figure S7B ).
Age at diagnosis of cancer according to the PPV carrier status
The age at diagnosis of cancer in the major cancer cohorts is shown in Figure S8 in the Supplementary Appendix. We compared the age according to the PPV carrier status, with emphasis on the cancer cohorts and PPV sets that underwent validation analysis. The age at diagnosis of cancer was lower in the PPV carriers in all evaluated cohorts (one-sided P<0.5; Figure 3A ). This difference was significant in the following cohorts: Pan-Cancer (median age, 59
versus 61 years; P=0.002), pancreatic adenocarcinoma (median age, 61 versus 68.5 years;
P<0.001), and chronic myeloid disorder (median age, 45.5 versus 58.5 years; P=0.044). In the entire Pan-Cancer cohort, carriers of PPVs in tier 1, tier 3, HGSNAT, CLN3, and NPC2 exhibited significantly earlier diagnosis of cancer ( Figure 3B) . Moreover, the PPV load (number of PPVs per individual) showed a significant negative linear correlation with age at diagnosis of cancer in the Pan-Cancer and pancreatic adenocarcinoma cohorts ( Figure S9 in the Supplementary Appendix).
Expanded analysis encompassing all histologies and genes revealed earlier cancer diagnosis in PPV carriers in five additional cancer-gene pairs ( Figure 3C ), three of which (pancreatic adenocarcinoma-MAN2B1, cutaneous melanoma-NPC2, and chronic myeloid disorder-SGSH)
were in concordance with the SKAT-O test results ( Figure 2D ). 
Somatic mutations and gene expression patterns in the PPV
development of Parkinson disease, Alzheimer disease, and Huntington disease, all of which have shown association with LSDs. 1 The glycerophospholipid metabolism pathway was also identified, indicating dysregulation in lysosomal function.
Supportive data
Additional supportive data are provided in the Supplementary Results section in the Supplementary Appendix.
Discussion
In this study, we revealed previously unidentified associations between the pathogenic germline mutations in LSD genes and cancer using global genome-wide sequencing data. Analysis by subgrouping of PPVs into three tiers based on different selection criteria, validation with an independent control cohort, and comparison of the results with those obtained by using synonymous variants with matched allele frequency all showed broadly consistent results, substantiating the robustness of findings in our study. The genetic association was further supported by the significant difference in age at diagnosis observed for PPV carriers of at least three histological subtypes as well as the Pan-Cancer cohort compared with the PPV-free cancer patients.
The lysosome is involved in many other cellular functions than biomolecule catabolism, such as intracellular signaling, nutrient sensing, cellular growth regulation, plasma membrane repair, and phagocytosis. 15 These diverse roles of the lysosome are consistent with complex phenotypes of LSDs which can involve virtually any organ. 1 It has long been evident that patients with Gaucher disease are at markedly increased risk of malignancy, especially multiple myeloma with the risk estimated at approximately 50-fold. 24 However, despite the largely shared pathogenesis, the relationship between most other LSDs and cancer has not been studied due to the rarity and phenotypic heterogeneity of each disease, leaving this area largely unexplored. The wide spectrum of tumor histologies and LSD genes covered in this study enabled elucidation of numerous cancer-gene pairwise associations most of which had previously been unknown.
In a gene-based analysis, we identified four genes showing a significant pan-cancer association; among those, SGSH and CLN3 were also strongly linked to five and four histological subtypes of cancer, respectively. SGSH encodes sulfamidase, a lysosomal hydrolase that degrades heparan sulfate. Deficiency of sulfamidase leads to Sanfilippo syndrome A (mucopolysaccharidosis IIIA), which is characterized by progressive mental and behavioral deterioration that typically presents in childhood. However, an adult-onset disease that presents primarily with visceral manifestations without neurological abnormality has also been reported. 25 A recent in vivo study showed the importance of oxidative stress in the pathobiology of Sanfilippo syndrome A. 26 Because the oxidative stress is also a key mediator of cancer cell growth, invasiveness, and angiogenesis, the inherited SGSH mutations may contribute to an elevated cancer risk via persistent cellular exposure to oxidative stress. 4 CLN3 is a late endosomal and lysosomal transmembrane protein, and its defect causes classic juvenile neuronal ceroid lipofuscinosis (CLN3 disease). In CLN3 disease, impaired trafficking of galactosylceramide to the plasma membrane promotes the generation of proapoptotic ceramide and subsequent activation of caspases, which in turn accelerates apoptosis. 14 In line with its control over apoptosis, CLN3 also regulates cancer cell growth, suggesting its therapeutic implications. 27 Results from our study warrant further investigation of this protein as a molecular target for cancer therapy.
Almost 5 to 10 percent of pancreatic cancer patients are diagnosed before the age of 50. 28 For these patients, positive family history is the most important risk factor, indicating the importance of inherited genetic variants. 29 Indeed, many predisposition genes have been identified (e.g.,
BRCA1/2 and PALB2).
However, in a majority of the early-onset pancreatic cancer patients, the cause remains unclear. 30 In our histology-specific analysis, pancreatic adenocarcinoma showed a particularly strong association with PPVs and early cancer diagnosis in mutation carriers, motivating us to evaluate signatures of somatic mutations and gene expression in this histological subset. The DEG analysis revealed many genes with a significantly higher or lower level of expression in PPV carriers, and GAGE analysis provided novel insights into the pathways that are involved in pancreatic carcinogenesis in these patients. Remarkably, many of these pathways were previously implicated in pancreatic cancer development in transcriptome and exome sequencing studies. 22, 23 In contrast, the somatic mutation burden and mutational signatures were comparable between the PPV-bearing and PPV-free tumors. Overall, these results suggest that transcriptional misregulation is a key mediator linking defective lysosomal function to pancreatic carcinogenesis. In addition, decades of research on tumor suppressor genes (TSGs) involved in hereditary cancer predisposition syndromes have proposed a continuum model of tumor suppression emphasizing the importance of subtle change in expression of TSGs in oncogenesis. 31 Given the rarity of individual PPVs, almost all PPV carriers observed in our study were heterozygous for the particular variants. Therefore, our findings corroborate the dosage effect model for LSD genes that was already suggested in a previous study. 9 It is important to note that the Pan-Cancer cohort consisted primarily of adult patients. Thus, highly pathogenic variants that cause fatal outcomes in childhood might be underrepresented in the selected PPVs. This can explain the higher-than-expected population PPV frequency and the relatively low ORs compared to those observed for known high-penetrance CPMs. 32, 33 In addition, the 1000 Genomes cohort is not a completely cancer-free population, because donors were selected based on their previous history at the time of enrollment. Therefore, it is not surprising that over one-tenth of the population carried PPVs.
This study has limitations. First, because we did not process the raw sequence data but used variant call sets downloaded online, the possibility of batch effects cannot be excluded, even considering the similarity in pipelines used to generate each data set. [10] [11] [12] Second, we could not adjust for the population structure in analysis of the ExAC cohort as a control because the individual-level genotype data were not accessible. However, the ExAC cohort represents a similar mix of populations to the Pan-Cancer cohort, with ~70% of the entire cohort comprised of the Americans and Europeans. 12 Therefore, consistent results from the validation analysis corroborate our findings. Third, an independent cancer cohort with a sufficient size was not available for external validation. Fourth, hematological malignancies such as myeloma, the most widely known LSD-associated cancer, were poorly represented in the Pan-Cancer cohort, and the numbers of patients with individual cancer types were not sufficiently large to draw reliable histology-specific conclusions.
From a therapeutic perspective, LSD genes are attractive targets because of the mechanistically intuitive nature of enzyme replacement and substrate reduction therapies. Enzyme replacement therapy has already been approved for at least seven LSDs. 34 Other promising therapeutic approaches include pharmacological chaperones, gene therapy, and compounds that "read through" the early stop codon introduced by nonsense mutations. 34 Although it is unclear whether preemptive treatment can prevent or delay long-term complications of LSDs such as cancer, our study renders it promising to utilize LSD therapies for individualized cancer prevention and treatment. In conclusion, the present study provides a comprehensive landscape of associations between germline mutations in LSD genes and cancer. Investigating the crosstalk between treatable metabolic diseases and cancer is crucial because it can form a basis for precision cancer Abbreviations of the histological subtypes are defined in Table S1 in the Supplementary Appendix.
EUR denotes European, AMR American, ASN East Asian, AFR African, and SAN South Asian. Table S1 in the Supplementary Appendix. RSV denotes rare synonymous variants, FDR false discovery rate, and SKAT-O optimal sequence kernel association test. Only pathways of particular interest discussed in the manuscript are shown in this figure, and all pathways with FDR <0.1 are shown in Figure S14 . ECM denotes extracellular matrix. 
